Protein kinase C: perfectly balanced

Critical Reviews in Biochemistry and Molecular Biology

Volumn 53, Issue 2, 2018, Pages 208-230

  Newton, Alexandra C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer s disease; cancer; diacylglycerol; phorbol esters; phosphorylation; Protein kinase C; pseudosubstrate; tumor suppressor

Indexed keywords

BRYOSTATIN; ISOENZYME; ONCOPROTEIN; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA II; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN;

ALZHEIMER DISEASE; C2 DOMAIN; CARBOXY TERMINAL SEQUENCE; CEREBELLAR ATAXIA; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GERMLINE MUTATION; HAPLOINSUFFICIENCY; HUMAN; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; SECOND MESSENGER;

ALZHEIMER DISEASE; ANIMALS; HUMANS; ISOENZYMES; MUTATION; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SECOND MESSENGER SYSTEMS; TUMOR SUPPRESSOR PROTEINS;

EID: 85043606785     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.1080/10409238.2018.1442408     Document Type: Review

References (242)

1. Abrahamsen H, O'Neill AK, Kannan N, Kruse N, Taylor SS, Jennings PA, Newton AC., 2012. Peptidyl-prolyl isomerase Pin1 controls down-regulation of conventional protein kinase C isozymes. J Biol Chem. 287:13262–13278.
2. Adachi N, Kobayashi T, Takahashi H, Kawasaki T, Shirai Y, Ueyama T, Matsuda T, Seki T, Sakai N, Saito N., 2008. Enzymological analysis of mutant protein kinase Cgamma causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis. J Biol Chem. 283:19854–19863.
3. Alfonso SI, Callender JA, Hooli B, Antal CE, Mullin K, Sherman MA, Lesne SE, Leitges M, Newton AC, Tanzi RE, et al. 2016. Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease. Sci Signal. 9:ra47.
4. Ali SA, Justilien V, Jamieson L, Murray NR, Fields AP., 2016. Protein kinase Cι Drives a NOTCH3-dependent stem-like phenotype in mutant KRAS lung adenocarcinoma. Cancer Cell. 29:367–378.
5. Allen-Petersen BL, Carter CJ, Ohm AM, Reyland ME., 2014. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene. 33:1306–1315.
6. Antal CE, Callender JA, Kornov AP, Taylor SS, Newton AC., 2015a. Intramolecular C2 domain-mediated autoinhibition of protein kinase CbII. Cell Reports. 12:1252–1260.
7. Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, et al. 2015b. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell. 160:489–502.
8. Antal CE, Violin JD, Kunkel MT, Skovso S, Newton AC., 2014. Intramolecular conformational changes optimize protein kinase C signaling. Chem Biol. 21:459–469.
9. Aziz MH, Wheeler DL, Bhamb B, Verma AK., 2006. Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2. Cancer Res. 66:713–722.
10. Bandyopadhyay G, Kanoh Y, Sajan MP, Standaert ML, Farese RV., 2000. Effects of adenoviral gene transfer of wild-type, constitutively active, and kinase-defective protein kinase C-lambda on insulin-stimulated glucose transport in L6 myotubes. Endocrinology. 141:4120–4127.
11. Bandyopadhyay G, Sajan MP, Kanoh Y, Standaert ML, Quon MJ, Lea-Currie R, Sen A, Farese RV., 2002. PKC-zeta mediates insulin effects on glucose transport in cultured preadipocyte-derived human adipocytes. J Clin Endocrinol Metab. 87:716–723.
12. Bandyopadhyay G, Standaert ML, Zhao L, Yu B, Avignon A, Galloway L, Karnam P, Moscat J, Farese RV., 1997. Activation of protein kinase C (alpha, beta, and zeta) by insulin in 3T3/L1 cells. Transfection studies suggest a role for PKC-zeta in glucose transport. J Biol Chem. 272:2551–2558.
13. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R., 2011. The moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme parameters. Biochemistry. 50:4402–4410.
14. Barcelo C, Paco N, Morell M, Alvarez-Moya B, Bota-Rabassedas N, Jaumot M, Vilardell F, Capella G, Agell N., 2014. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res. 74:1190–1199.
15. Basu A, Pal D., 2010. Two faces of protein kinase Cδ: the contrasting roles of PKCδ in cell survival and cell death. Sci World J. 10:2272–2284.
16. Behn-Krappa A, Newton AC., 1999. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr Biol. 9:728–737.
17. Belot A, Kasher PR, Trotter EW, Foray AP, Debaud AL, Rice GI, Szynkiewicz M, Zabot MT, Rouvet I, Bhaskar SS, et al. 2013. Protein kinase cδ deficiency causes Mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 65:2161–2171.
18. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP., 2005. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 121:271–280.
19. Berenblum I, Shubik P., 1947. The role of croton oil applications, associated with a single painting of a carcinogen, in tumour induction of the mouse's skin. Br J Cancer. 1:379–382.
20. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, et al. 2005. An international cohort study of cancer in systemic lupus erythematosus [Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Arthritis Rheum. 52:1481–1490.
21. Betschinger J, Mechtler K, Knoblich JA., 2003. The Par complex directs asymmetric cell division by phosphorylating the cytoskeletal protein Lgl. Nature. 422:326–330.
22. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, et al. 2006. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Mol Cell. 21:481–493.
23. Blumberg PM, Jaken S, Konig B, Sharkey NA, Leach KL, Jeng AY, Yeh E., 1984. Mechanism of action of the phorbol ester tumor promoters: specific receptors for lipophilic ligands. Biochem Pharmacol. 33:933–940.
24. Bornancin F, Parker PJ., 1997. Phosphorylation of protein kinase C-alpha on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase- resistant state. J Biol Chem. 272:3544–3549.
25. Borner C, Filipuzzi I, Wartmann M, Eppenberger U, Fabbro D., 1989. Biosynthesis and posttranslational modifications of protein kinase C in human breast cancer cells. J Biol Chem. 264:13902–13909.
26. Bowers BJ, Collins AC, Tritto T, Wehner JM., 2000. Mice lacking PKC gamma exhibit decreased anxiety. Behav Genet. 30:111–121.
27. Brodie C, Blumberg PM., 2003. Regulation of cell apoptosis by protein kinase c delta. Apoptosis. 8:19–27.
28. Callender JA, Yang Y, Stephenson N, Brognard J, Newton AC., 2018. Protein kinase Cα (PKCα) gain-of-function variant in Alzheimer’s disease displays enhanced catalysis by mechanism that evades down-regulation. FASEB J: Off Publ Feder Am Soc Exp Biol. In press.
29. Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ., 2011. mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem J. 439:287–297.
30. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y., 1982. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting Phorbol Esters. J Biol Chem. 257:7847–7851.
31. Cenni V, Doppler H, Sonnenburg ED, Maraldi N, Newton AC, Toker A., 2002. Regulation of novel protein kinase C epsilon by phosphorylation. Biochem J. 363:537–545.
32. Corbalan-Garcia S, Garcia-Garcia J, Rodriguez-Alfaro JA, Gomez-Fernandez JC., 2003. A new phosphatidylinositol 4,5-bisphosphate-binding site located in the C2 domain of protein kinase Calpha [Research Support, Non-U.S. Gov't]. J Biol Chem. 278:4972–4980.
33. Coussens L, Parker PJ, Rhee L, Yang-Feng TL, Chen E, Waterfield MD, Francke U, Ullrich A., 1986. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science. 233:859–866.
34. Creixell P, Schoof EM, Simpson CD, Longden J, Miller CJ, Lou HJ, Perryman L, Cox TR, Zivanovic N, Palmeri A, et al. 2015. Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. Cell. 163:202–217.
35. de Vries DJ, Herald CL, Pettit GR, Blumberg PM., 1988. Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain. Biochem Pharmacol. 37:4069–4073.
36. Ding YQ, Xiang CX, Chen ZF., 2005. Generation and characterization of the PKC gamma-Cre mouse line. Genesis. 43:28–33.
37. Don AS, Zheng XF., 2011. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials. 6:24–35.
38. Dowling CM, Phelan J, Callender JA, Cathcart MC, Mehigan B, McCormick P, Dalton T, Coffey JC, Newton AC, O'Sullivan J, et al. 2016. Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival. Oncotarget. 7:20919–20933.
39. Driedger PE, Blumberg PM., 1980. Specific binding of Phorbol Ester tumor promoters. Proc Natl Acad Sci USA. 77:567–571.
40. Dries DR, Gallegos LL, Newton AC., 2007. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J Biol Chem. 282:826–830.
41. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP, Seshadri S, Wolf PA., 2012. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ. 344:e1442.
42. Drummond ML, Prehoda KE., 2016. Molecular control of atypical protein kinase C: tipping the balance between self-renewal and differentiation. J Mol Biol. 428:1455–1464.
43. Edwards AS, Newton AC., 1997. Phosphorylation at conserved carboxyl-terminal hydrophobic motif regulates the catalytic and regulatory domains of protein kinase C. J Biol Chem. 272:18382–18390.
44. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al. 2008. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. EMBO J. 27:1932–1943.
45. Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR, Jr, Nimal S, Choi CS, Kim S, Shulman GI, et al. 2007. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest. 117:2289–2301.
46. Flint AJ, Paladini RD, Koshland DE, Jr.1990. Autophosphorylation of protein kinase C at three separated regions of its primary sequence. Science. 249:408–411.
47. Freeley M, Kelleher D, Long A., 2011. Regulation of Protein Kinase C function by phosphorylation on conserved and non-conserved sites [Review]. Cell Signal. 23:753–762.
48. Frey MR, Saxon ML, Zhao X, Rollins A, Evans SS, Black JD., 1997. Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J Biol Chem. 272:9424–9435.
49. Fujimoto K, Ohta K, Kangawa K, Kikkawa U, Ogino S, Fukui H., 1999. Identification of protein kinase C phosphorylation sites involved in phorbol ester-induced desensitization of the histamine H1 receptor. Mol Pharmacol. 55:735–742.
50. Gallegos LL, Kunkel MT, Newton AC., 2006. Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J Biol Chem. 281:30947–30956.
51. Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S, Leitges M, Diaz-Meco MT, Moscat J., 2009. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. Mol Cell Biol. 29:104–115.
52. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl1.
53. Gao T, Brognard J, Newton AC., 2008. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem. 283:6300–6311.
54. Gao T, Newton AC., 2006. Invariant Leu preceding turn motif phosphorylation site controls the interaction of protein kinase C with Hsp70. J Biol Chem. 281:32461–32468.
55. Gao T, Toker A, Newton AC., 2001. The carboxyl terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, pdk-1. J Biol Chem. 276:19588–19596.
56. Garcia-Paramio P, Cabrerizo Y, Bornancin F, Parker PJ., 1998. The broad specificity of dominant inhibitory protein kinase C mutants infers a common step in phosphorylation. Biochem J. 333:631–636.
57. Garg R, Benedetti LG, Abera MB, Wang H, Abba M, Kazanietz MG., 2014. Protein kinase C and cancer: what we know and what we do not. Oncogene. 33:5225–5237.
58. Garg R, Blando JM, Perez CJ, Abba MC, Benavides F, Kazanietz MG., 2017. Protein kinase C epsilon cooperates with PTEN loss for prostate tumorigenesis through the CXCL13-CXCR5 pathway. Cell Rep. 19:375–388.
59. Giorgione J, Hysell M, Harvey DF, Newton AC., 2003. Contribution of the C1A and C1B domains to the membrane interaction of protein kinase C. Biochemistry. 42:11194–11202.
60. Giorgione JR, Lin JH, McCammon JA, Newton AC., 2006. Increased membrane affinity of the C1 domain of protein kinase Cdelta compensates for the lack of involvement of its C2 domain in membrane recruitment. J Biol Chem. 281:1660–1669.
61. Gong J, Holewinski RJ, Van Eyk JE, Steinberg SF., 2016. A novel phosphorylation site at Ser130 adjacent to the pseudosubstrate domain contributes to the activation of protein kinase C-δ. Biochem J. 473:311–320.
62. Goto Y, Hishida A, Matsuo K, Tajima K, Morita E, Naito M, Wakai K, Hamajima N., 2010. PRKCH gene polymorphism is associated with the risk of severe gastric atrophy. Gastric Cancer. 13:90–94.
63. Gould CM, Kannan N, Taylor SS, Newton AC., 2009. The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. J Biol Chem. 284:4921–4935.
64. Graybill C, Wee B, Atwood SX, Prehoda KE., 2012. Partitioning-defective protein 6 (Par-6) activates atypical protein kinase C (aPKC) by pseudosubstrate displacement. J Biol Chem. 287:21003–21011.
65. Griner EM, Kazanietz MG., 2007. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 7:281–294.
66. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM., 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 11:859–871.
67. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731.
68. Hafeez BB, Zhong W, Weichert J, Dreckschmidt NE, Jamal MS, Verma AK., 2011. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res. 71:2318–2327.
69. Hanks SK, Hunter T., 1995. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:576–596.
70. Hansra G, Garcia-Paramio P, Prevostel C, Whelan RD, Bornancin F, Parker PJ., 1999. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes [In Process Citation]. Biochem J. 342:337–344.
71. Hecker E., 1968. Cocarcinogenic principles from the seed oil of Croton tiglium and from other Euphorbiaceae. Cancer Res. 28:2338–2349.
72. Hecker E., 1978. Co-carcinogens or modulators of carcinogenesis. New aspects of the etiology of human tumors and of the molecular mechanisms of carcinogenesis. Naturwissenschaften. 65:640–648.
73. Hecker E, Kubinyi H, Bresch H, von Szczepanski C., 1966. The chemical structure of a cocarcinogen and of phorbol isolated from croton oil. J Med Chem. 9:246–247.
74. Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F, et al. 2015. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 163:712–723.
75. Hernandez AI, Blace N, Crary JF, Serrano PA, Leitges M, Libien JM, Weinstein G, Tcherapanov A, Sacktor TC., 2003. Protein Kinase M zeta synthesis from a brain mRNA encoding an independent protein kinase C zeta catalytic domain. Implications for the molecular mechanism of memory. J Biol Chem. 278:40305–40316.
76. Hirose T, Izumi Y, Nagashima Y, Tamai-Nagai Y, Kurihara H, Sakai T, Suzuki Y, Yamanaka T, Suzuki A, Mizuno K, et al. 2002. Involvement of ASIP/PAR-3 in the promotion of epithelial tight junction formation. J Cell Sci. 115:2485–2495.
77. Hokin LE., 1987. The road to the phosphoinositide-generated second messengers. Trends Pharmacol Sci. 8:53–56.
78. Hokin MR, Hokin LE., 1953. Enzyme secretion and the incorporation of P32 into phospholipides of pancreas slices. J Biol Chem. 203:967–977.
79. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, Sullivan M., 2012. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse [Research Support, N.I.H., Extramural]. Nucleic Acids Res. 40:D261–D270.
80. Hosey MM, Benovic JL, DebBurman SK, Richardson RM., 1995. Multiple mechanisms involving protein phosphorylation are linked to desensitization of muscarinic receptors. Life Sci. 56:951–955.
81. Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD., 2010. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell. 37:541–550.
82. House C, Kemp BE., 1987. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science. 238:1726–1728.
83. House C, Kemp BE., 1990. Protein kinase C pseudosubstrate prototope: structure-function relationships. Cell Sig. 2:187–190.
84. 2+-activated and phospholipid-dependent protein kinase. Proc Natl Acad Sci USA. 83:8535–8539.
85. Humphries MJ, Ohm AM, Schaack J, Adwan TS, Reyland ME., 2008. Tyrosine phosphorylation regulates nuclear translocation of PKCdelta. Oncogene. 27:3045–3053.
86. Hunter T, Ling N, Cooper JA., 1984. Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature. 311:480–483.
87. Iglesias T, Matthews S, Rozengurt E., 1998. Dissimilar phorbol ester binding properties of the individual cysteine-rich motifs of protein kinase D. FEBS Lett. 437:19–23.
88. Igumenova TI., 2015. Dynamics and membrane interactions of protein kinase C. Biochemistry. 54:4953–4968.
89. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL., 2008. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. EMBO J. 27:1919–1931.
90. Inoue M, Kishimoto A, Takai Y, Nishizuka Y., 1977. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem. 252:7610–7616.
91. Isakov N., 2017. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 48:36–52.
92. Isakov N, Gopas J, Priel E, Segal S, Altman A., 1991. Effect of protein kinase C activating tumor promoters on metastases formation by fibrosarcoma cells. Invasion Metastasis. 11:14–24.
93. Jaken S, Tashjian AH, Jr, Blumberg PM., 1981. Characterization of phorbol ester receptors and their down-modulation in GH4C1 rat pituitary cells [Research Support, U.S. Gov't, P.H.S.]. Cancer Res. 41:2175–2181.
94. Johannes F-J, Prestle J, Eis S, Oberhagemann P, Pfizenmaier K., 1994. PKCu is a novel, atypical member of the protein kinase C family. J Biol Chem. 269:6140–6148.
95. Johnson JE, Edwards AS, Newton AC., 1997. A putative phosphatidylserine binding motif is not involved in the lipid regulation of protein kinase C. J Biol Chem. 272:30787–30792.
96. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP., 2014. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 25:139–151.
97. Kannan N, Haste N, Taylor SS, Neuwald AF., 2007. The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci USA. 104:1272–1277.
98. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, et al. 2015. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 47:1304–1315.
99. Kazanietz MG., 2000. Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog. 28:5–11.
100. Kazanietz MG, Areces LB, Bahador A, Mischak H, Goodnight J, Mushinski JF, Blumberg PM., 1993. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol. 44:298–307.
101. Kazanietz MG, Bustelo XR, Barbacid M, Kolch W, Mischak H, Wong G, Pettit GR, Bruns JD, Blumberg PM., 1994. Zinc finger domains and Phorbol Ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem. 269:11590–11594.
102. Keranen LM, Dutil EM, Newton AC., 1995. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol. 5:1394–1403.
103. Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y., 1983. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem. 258:11442–11445.
104. Kiykim A, Ogulur I, Baris S, Salzer E, Karakoc-Aydiner E, Ozen AO, Garncarz W, Hirschmugl T, Krolo A, Yucelten AD, et al. 2015. Potentially beneficial effect of hydroxychloroquine in a patient with a novel mutation in protein kinase Cdelta deficiency. J Clin Immunol. 35:523–526.
105. Knauf JA, Elisei R, Mochly-Rosen D, Liron T, Chen XN, Gonsky R, Korenberg JR, Fagin JA., 1999. Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. J Biol Chem. 274:23414–23425.
106. Knopf JL, Lee M-H, Sultzman LA, Kriz RW, Loomis CR, Hewick RM, Bell RM., 1986. Cloning and expression of multiple protein kinase C cDNAs. Cell. 46:491–502.
107. Kohout SC, Corbalan-Garcia S, Torrecillas A, Gomez-Fernandez JC, Falke JJ., 2002. C2 domains of protein kinase C isoforms alpha, beta, and gamma: activation parameters and calcium stoichiometries of the membrane-bound state. Biochemistry. 41:11411–11424.
108. König B, DiNitto PA, Blumberg PM., 1985. Stoichiometric binding of diacylglycerol to the Phorbol Ester Receptor. J Cell Biochem. 29:37–44.
109. 2. Proc Natl Acad Sci USA. 94:11233–11237.
110. Koren R, Langzam L, Paz A, Livne PM, Gal R, Sampson SR., 2000. Protein kinase C (PKC) isoenzymes immunohistochemistry in lymph node revealing solution-fixed, paraffin-embedded bladder tumors. Appl Immunohistochem Mol Morphol: AIMM/Off Publ Soc Appl Immunohistochem. 8:166–171.
111. Kotani K, Ogawa W, Matsumoto M, Kitamura T, Sakaue H, Hino Y, Miyake K, Sano W, Akimoto K, Ohno S, et al. 1998. Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol. 18:6971–6982.
112. Kraft AS, Smith JB, Berkow RL., 1986. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA. 83:1334–1338.
113. Kubo M, Hata J, Ninomiya T, Matsuda K, Yonemoto K, Nakano T, Matsushita T, Yamazaki K, Ohnishi Y, Saito S, et al. 2007. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet. 39:212–217.
114. Kuehn HS, Niemela JE, Rangel-Santos A, Zhang M, Pittaluga S, Stoddard JL, Hussey AA, Evbuomwan MO, Priel DA, Kuhns DB, et al. 2013. Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. Blood. 121:3117–3125.
115. Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, et al. 2014. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Sci Signal. 7:ra75.
116. Langzam L, Koren R, Gal R, Kugel V, Paz A, Farkas A, Sampson SR., 2001. Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy [Comparative Study Research Support, Non-U.S. Gov't]. Am J Clin Pathol. 116:377–385.
117. Leonard TA, Rozycki B, Saidi LF, Hummer G, Hurley JH., 2011. Crystal structure and allosteric activation of protein kinase C βII. Cell. 144:55–66.
118. Levin DE, Fields FO, Kunisawa R, Bishop JM, Thorner J., 1990. A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle. Cell. 62:213–224.
119. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T., 2000. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol. 2:540–547.
120. Linch M, Sanz-Garcia M, Soriano E, Zhang Y, Riou P, Rosse C, Cameron A, Knowles P, Purkiss A, Kjaer S, et al. 2013. A cancer-associated mutation in atypical protein kinase Ciota occurs in a substrate-specific recruitment motif. Sci Signal. 6:ra82.
121. Littler DR, Walker JR, She YM, Finerty PJ, Jr, Newman EM, Dhe-Paganon S., 2006. Structure of human protein kinase C eta (PKCeta) C2 domain and identification of phosphorylation sites [Research Support, Non-U.S. Gov't]. Biochem Biophys Res Commun. 349:1182–1189.
122. Livneh E, Dull TJ, Berent E, Prywes R, Ullrich A, Schlessinger J., 1988. Release of a phorbol ester-induced mitogenic block by mutation at Thr-654 of the epidermal growth factor receptor. Mol Cell Biol. 8:2302–2308.
123. Livneh E, Reiss N, Berent E, Ullrich A, Schlessinger J., 1987. An insertional mutant of epidermal growth factor receptor allows dissection of diverse receptor functions. EMBO J. 6:2669–2676.
124. Llado V, Nakanishi Y, Duran A, Reina-Campos M, Shelton PM, Linares JF, Yajima T, Campos A, Aza-Blanc P, Leitges M, et al. 2015. Repression of intestinal stem cell function and tumorigenesis through direct phosphorylation of beta-Catenin and Yap by PKCzeta. Cell Rep. [accessed 2015 Feb 4]. https://doi.org/10.1016/j.celrep.2015.01.007
125. Lu HC, Chou FP, Yeh KT, Chang YS, Hsu NC, Chang JG., 2009. Analysing the expression of protein kinase C eta in human hepatocellular carcinoma. Pathology. 41:626–629.
126. Lum MA, Barger CJ, Hsu AH, Leontieva OV, Black AR, Black JD., 2016. Protein kinase calpha (PKCalpha) is resistant to long term desensitization/down-regulation by prolonged diacylglycerol stimulation. J Biol Chem. 291:6331–6346.
127. Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, Castilla EA, Chen J, Yajima T, Porollo A, et al. 2013. Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. Cell. 152:599–611.
128. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S., 2002. The protein kinase complement of the human genome. Science. 298:1912–1934.
129. Marshall JL, Bangalore N, El-Ashry D, Fuxman Y, Johnson M, Norris B, Oberst M, Ness E, Wojtowicz-Praga S, Bhargava P, et al. 2002. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies. Cancer Biol Ther. 1:409–416.
130. Mauro LV, Grossoni VC, Urtreger AJ, Yang C, Colombo LL, Morandi A, Pallotta MG, Kazanietz MG, Bal de Kier Joffe ED, Puricelli LL., 2010. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer [Research Support, Non-U.S. Gov't]. Pancreas. 39:e31–e41.
131. Mayati A, Moreau A, Le Vee M, Stieger B, Denizot C, Parmentier Y, Fardel O., 2017. Protein kinases C-mediated regulations of drug transporter activity, localization and expression. IJMS. 18:764.
132. McClendon CL, Kornev AP, Gilson MK, Taylor SS., 2014. Dynamic architecture of a protein kinase. Proc Natl Acad Sci USA. 111:E4623–46E4631.
133. McKiernan E, O'Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, Magdolen V, Evoy D, McDermott E, Crown J, et al. 2008. Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer. 99:1644–1650.
134. McSkimming DI, Dastgheib S, Baffi TR, Byrne DP, Ferries S, Scott ST, Newton AC, Eyers CE, Kochut KJ, Eyers PA, et al. 2016. KinView: a visual comparative sequence analysis tool for integrated kinome research. Mol Biosyst. 12:3651–3665.
135. Meharena HS, Chang P, Keshwani MM, Oruganty K, Nene AK, Kannan N, Taylor SS, Kornev AP., 2013. Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol. 11:e1001680.
136. Michell RH., 1975. Inositol phospholipids and cell surface receptor function. Biochim Biophys Acta. 415:81–147.
137. Milani G, Rebora P, Accordi B, Galla L, Bresolin S, Cazzaniga G, Buldini B, Mura R, Ladogana S, Giraldi E, et al. 2014. Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget. 5:5234–5245.
138. Morales KA, Yang Y, Cole TR, Igumenova TI., 2016. Dynamic response of the C2 domain of protein kinase Calpha to Ca(2+) binding. Biophys J. 111:1655–1667.
139. Nagai-Tamai Y, Mizuno K, Hirose T, Suzuki A, Ohno S., 2002. Regulated protein-protein interaction between aPKC and PAR-3 plays an essential role in the polarization of epithelial cells. Genes Cells. 7:1161–1171.
140. Nakanishi H, Exton JH., 1992. Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J Biol Chem. 267:16347–16354.
141. Nakanishi Y, Reina-Campos M, Nakanishi N, Llado V, Elmen L, Peterson S, Campos A, De SK, Leitges M, Ikeuchi H, et al. 2016. Control of paneth cell fate, intestinal inflammation, and tumorigenesis by PKCλ/ι. Cell Rep. 16:3297–3310.
142. Nalefski EA, Falke JJ., 1996. The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci. 5:2375–2390.
143. Nalefski EA, Wisner MA, Chen JZ, Sprang SR, Fukuda M, Mikoshiba K, Falke JJ., 2001. C2 domains from different Ca2+ signaling pathways display functional and mechanistic diversity [Comparative Study Research Support, U.S. Gov't, P.H.S.]. Biochemistry. 40:3089–3100.
144. Namkung Y, Sibley DR., 2004. Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. J Biol Chem. 279:49533–49541.
145. Neckers L, Workman P., 2012. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res: Off J Am Assoc Cancer Res. 18:64–76.
146. Nelson TJ, Sun MK, Lim C, Sen A, Khan T, Chirila FV, Alkon DL., 2017. Bryostatin effects on cognitive function and PKCɛ in Alzheimer's disease Phase IIa and expanded access trials. J Alzheimers Dis. 58:521–535.
147. Newton AC., 2010. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab. 298:E395–E402.
148. Newton AC, Johnson JE., 1998. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta. 1376:155–172.
149. Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ., 2004. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol. 93:144–148.
150. Ng T, Squire A, Hansra G, Bornancin F, Prevostel C, Hanby A, Harris W, Barnes D, Schmidt S, Mellor H, et al. 1999. Imaging protein kinase Calpha activation in cells. Science. 283:2085–2089.
151. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC., 1997. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem. 272:952–960.
152. Nishizuka Y., 1992. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:607–614.
153. Ohno S, Akita Y, Konno Y, Imajoh S, Suzuki K., 1988. A novel Phorbol Ester receptor/protein kinase, nPKC, distantly related to the protein kinase C family. Cell. 53:731–741.
154. Olive MF, Messing RO., 2004. Protein kinase C isozymes and addiction. Mol Neurobiol. 29:139–154.
155. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y., 1988. The structure, expression, and properties of additional members of the protein kinase C family. J Biol Chem. 263:6927–6932.
156. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y., 1989. Protein kinase C zeta subspecies from rat brain: its structure, expression, and properties. Proc Natl Acad Sci USA. 86:3099–3103.
157. Ono Y, Kikkawa U, Ogita K, Fujii T, Kurokawa T, Asaoka Y, Sekiguchi K, Ase K, Igarashi K, Nishizuka Y., 1987. Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science. 236:1116–1120.
158. Orr JW, Keranen LM, Newton AC., 1992. Reversible exposure of the pseudosubstrate domain of protein kinase C by phosphatidylserine and diacylglycerol. J Biol Chem. 267:15263–15266.
159. Ouyang X, Gulliford T, Epstein RJ., 1998. The duration of phorbol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signalling. Carcinogenesis. 19:2013–2019.
160. Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D., 2009. Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res. 82:229–239.
161. Parker PJ, Coussens L, Totty N, Rhee L, Young S, Chen E, Stabel S, Waterfield MD, Ullrich A., 1986. The complete primary structure of protein kinase C-the major Phorbol Ester receptor. Science. 233:853–859.
162. Parker PJ, Justilien V, Riou P, Linch M, Fields AP., 2014. Atypical protein kinase Cι as a human oncogene and therapeutic target. Biochem Pharmacol. 88:1–11.
163. Parker PJ, Parkinson SJ., 2001. AGC protein kinase phosphorylation and protein kinase C. Biochem Soc Trans. 29:860–863.
164. Patel NA, Song SS, Cooper DR., 2006. PKCdelta alternatively spliced isoforms modulate cellular apoptosis in retinoic acid-induced differentiation of human NT2 cells and mouse embryonic stem cells. Gene Expr. 13:73–84.
165. Payne SR, Kemp CJ., 2005. Tumor suppressor genetics [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Carcinogenesis. 26:2031–2045.
166. Pepio AM, Sossin WS., 2001. Membrane translocation of novel protein kinase Cs is regulated by phosphorylation of the C2 domain. J Biol Chem. 276:3846–3855.
167. Pitcher J, Lohse MJ, Codina J, Caron MG, Lefkowitz RJ., 1992. Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry. 31:3193–3197.
168. Plant PJ, Fawcett JP, Lin DC, Holdorf AD, Binns K, Kulkarni S, Pawson T., 2003. A polarity complex of mPar-6 and atypical PKC binds, phosphorylates and regulates mammalian Lgl. Nat Cell Biol. 5:301–308.
169. Prevostel C, Alice V, Joubert D, Parker PJ., 2000. Protein kinase C(alpha) actively downregulates through caveolae-dependent traffic to an endosomal compartment. J Cell Sci. 113:2575–2584.
170. Prevostel C, Alvaro V, de Boisvilliers F, Martin A, Jaffiol C, Joubert D., 1995. The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene. 11:669–674.
171. Pu Y, Garfield SH, Kedei N, Blumberg PM., 2009. Characterization of the differential roles of the twin C1a and C1b domains of protein kinase C-delta. J Biol Chem. 284:1302–1312.
172. Pu Y, Peach ML, Garfield SH, Wincovitch S, Marquez VE, Blumberg PM., 2006. Effects on ligand interaction and membrane translocation of the positively charged arginine residues situated along the C1 domain binding cleft in the atypical protein kinase C isoforms. J Biol Chem. 281:33773–33788.
173. Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng CP, Zou J, Oberley TD, Verma AK., 1999. Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 59:5710–5718.
174. Reddig PJ, Dreckschmidt NE, Zou J, Bourguignon SE, Oberley TD, Verma AK., 2000. Transgenic mice overexpressing protein kinase C epsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion. Cancer Res. 60:595–602.
175. Reyland ME., 2007. Protein kinase Cdelta and apoptosis. Biochem Soc Trans. 35:1001–1004.
176. Reyland ME., 2009. Protein kinase C isoforms: multi-functional regulators of cell life and death [Review]. Front Biosci. 2386–2399.
177. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC., 2005. Alzheimer disease and cancer. Neurology. 64:895–898.
178. Roelants FM, Leskoske KL, Martinez Marshall MN, Locke MN, Thorner J., 2017. The TORC2-dependent signaling network in the yeast Saccharomyces cerevisiae. Biomolecules. 7.
179. Ron D, Messing RO., 2013. Signaling pathways mediating alcohol effects. Curr Top Behav Neurosci. 13:87–126.
180. Russo P, Kisialiou A, Lamonaca P, Moroni R, Prinzi G, Fini M., 2015. New drugs from marine organisms in Alzheimer's disease. Mar Drugs. 14.
181. Ryckbosch SM, Wender PA, Pande VS., 2017. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nat Commun. 8:6.
182. Sajan MP, Rivas J, Li P, Standaert ML, Farese RV., 2006. Repletion of atypical protein kinase C following RNA interference-mediated depletion restores insulin-stimulated glucose transport. J Biol Chem. 281:17466–17473.
183. Salzer E, Santos-Valente E, Keller B, Warnatz K, Boztug K., 2016. Protein kinase C δ: a gatekeeper of immune homeostasis. J Clin Immunol. 36:631–640.
184. Salzer E, Santos-Valente E, Klaver S, Ban SA, Emminger W, Prengemann NK, Garncarz W, Mullauer L, Kain R, Boztug H, et al. 2013. B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ. Blood. 121:3112–3116.
185. Sanchez-Bautista S, Marin-Vicente C, Gomez-Fernandez JC, Corbalan-Garcia S., 2006. The C2 domain of PKCalpha is a Ca2+ -dependent PtdIns(4,5)P2 sensing domain: a new insight into an old pathway [Research Support, Non-U.S. Gov't]. J Mol Biol. 362:901–914.
186. Santiskulvong C, Rozengurt E., 2007. Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by Gq-coupled receptor agonists [Research Support, N.I.H., Extramural]. Cell Signal. 19:1348–1357.
187. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM., 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 14:1296–1302.
188. Saxon ML, Zhao X, Black JD., 1994. Activation of protein kinase C isozymes is associated with post-mitotic events in intestinal epithelial cells in situ. J Cell Biol. 126:747–763.
189. Schrott LM, Jackson K, Yi P, Dietz F, Johnson GS, Basting TF, Purdum G, Tyler T, Rios JD, Castor TP, et al. 2015. Acute oral Bryostatin-1 administration improves learning deficits in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res. 12:22–31.
190. Schwendt M, Olive MF., 2017. Protein kinase Cɛ activity regulates mGluR5 surface expression in the rat nucleus accumbens. J Neurosci Res. 95:1079–1090.
191. Scott JD, Glaccum MB, Fischer EH, Krebs EG., 1986. Primary-structure requirements for inhibition by the heat-stable inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci USA. 83:1613–1616.
192. Sharkey NA, Leach KL, Blumberg PM., 1984. Competitive inhibition by diacylglycerol of specific Phorbol Ester binding. Proc Natl Acad Sci USA. 81:607–610.
193. Shi HB, Tang B, Liu YW, Wang XF, Chen GJ., 2015. Alzheimer disease and cancer risk: a meta-analysis. J Cancer Res Clin Oncol. 141:485–494.
194. Sipeki S, Bander E, Parker PJ, Farago A., 2006. PKCalpha reduces the lipid kinase activity of the p110alpha/p85alpha PI3K through the phosphorylation of the catalytic subunit. Biochem Biophys Res Commun. 339:122–125.
195. Sommese RF, Ritt M, Swanson CJ, Sivaramakrishnan S., 2017. The role of regulatory domains in maintaining autoinhibition in the multidomain kinase PKCα. J Biol Chem. 292:2873–2880.
196. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H, Cantley LC., 1994. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol. 4:973–982.
197. Sonnenburg ED, Gao T, Newton AC., 2001. The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide 3-kinase. J Biol Chem. 276:45289–45297.
198. Soriano EV, Ivanova ME, Fletcher G, Riou P, Knowles PP, Barnouin K, Purkiss A, Kostelecky B, Saiu P, Linch M, et al. 2016. aPKC inhibition by Par3 CR3 flanking regions controls substrate access and underpins apical-junctional polarization. Dev Cell. 38:384–398.
199. Steinberg SF., 2004. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J. 384:449–459.
200. Stempka L, Girod A, Müller H-J, Rincke G, Marks F, Gschwendt M, Bossemeyer D., 1997. Phosphorylation of protein kinase Cdelta (PKCdelta) at threonine 505 is not a prerequisite for enzymatic activity. Expression of rat PKCdelta and an alanine 505 mutant in bacteria in a functional form. J Biol Chem. 272:6805–6811.
201. Stewart MD, Igumenova TI., 2017. Toggling of diacylglycerol affinity correlates with conformational plasticity in C1 domains. Biochemistry. 56:2637–2640.
202. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C., 2014. The landscape of kinase fusions in cancer. Nat Commun. 5:4846.
203. Streb H, Irvine RF, Berridge MJ, Schulz I., 1983. Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature. 306:67–69.
204. Symonds JM, Ohm AM, Carter CJ, Heasley LE, Boyle TA, Franklin WA, Reyland ME., 2011. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 71:2087–2097.
205. Szallasi Z, Blumberg PM., 1991. Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. Cancer Res. 51:5355–5360.
206. Szallasi Z, Bogi K, Gohari S, Biro T, Acs P, Blumberg PM., 1996. Non-equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells. J Biol Chem. 271:18299–18301.
207. Szallasi Z, Smith CB, Pettit GR, Blumberg PM., 1994. Differential regulation of protein kinase C isozymes by Bryostatin 1 and Phorbol 12-Myristate 13-Acetate in NIH 3T3 fibroblasts. J Biol Chem. 269:2118–2124.
208. Tagawa K, Homma H, Saito A, Fujita K, Chen X, Imoto S, Oka T, Ito H, Motoki K, Yoshida C, et al. 2015. Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. Hum Mol Genet. 24:540–558.
209. Takahashi H, Adachi N, Shirafuji T, Danno S, Ueyama T, Vendruscolo M, Shuvaev AN, Sugimoto T, Seki T, Hamada D, et al. 2015. Identification and characterization of PKCγ, a kinase associated with SCA14, as an amyloidogenic protein. Hum Mol Genet. 24:525–539.
210. Takai Y, Kishimoto A, Inoue M, Nishizuka Y., 1977. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem. 252:7603–7609.
211. Takai Y, Kishimoto A, Iwasa Y, Kawahara Y, Mori T, Nishizuka Y., 1979a. Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. J Biol Chem. 254:3692–3695.
212. Takai Y, Kishimoto A, Iwasa Y, Kawahara Y, Mori T, Nishizuka Y, Tamura A, Fujii T., 1979b. A role of membranes in the activation of a new multifunctional protein kinase system. J Biochem. 86:575–578.
213. Takai Y, Kishimoto A, Kikkawa U, Mori T, Nishizuka Y., 1979c. Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. Biochem Biophys Res Commun. 91:1218–1224.
214. Takata Y, Hamada D, Miyatake K, Nakano S, Shinomiya F, Scafe CR, Reeve VM, Osabe D, Moritani M, Kunika K, et al. 2007. Genetic association between the PRKCH gene encoding protein kinase Ceta isozyme and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 56:30–42.
215. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG., 2003. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem. 278:33753–33762.
216. Taylor SS, Kornev AP., 2011. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci. 36:65–77.
217. Tobias IS, Kaulich M, Kim PK, Simon N, Jacinto E, Dowdy SF, King CC, Newton AC., 2016. Protein kinase Cζ exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation. Biochem J. 473:509–523.
218. Tobias IS, Newton AC., 2016. Protein scaffolds control localized protein kinase C zeta Activity. J Biol Chem. 291:13809–13822.
219. Toker A., 2005. The biology and biochemistry of diacylglycerol signalling. Meeting on molecular advances in diacylglycerol signalling. EMBO Rep. 6:310–314.
220. Torkamani A, Kannan N, Taylor SS, Schork NJ., 2008. Congenital disease SNPs target lineage specific structural elements in protein kinases. Proc Natl Acad Sci USA. 105:9011–9016.
221. Trujillo JI, Kiefer JR, Huang W, Thorarensen A, Xing L, Caspers NL, Day JE, Mathis KJ, Kretzmer KK, Reitz BA, et al. 2009. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett. 19:908–911.
222. Tsai LC, Xie L, Dore K, Xie L, Del Rio JC, King CC, Martinez-Ariza G, Hulme C, Malinow R, Bourne PE, et al. 2015. Zeta inhibitory peptide disrupts electrostatic interactions that maintain atypical protein kinase C in its active conformation on the scaffold p62. J Biol Chem. 290:21845–21856.
223. Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al. 2017. A pathology atlas of the human cancer transcriptome. Science. 357:660.
224. Vallentin A, Lo TC, Joubert D., 2001. A single point mutation in the V3 region affects protein kinase Calpha targeting and accumulation at cell-cell contacts. Mol Cell Biol. 21:3351–3363.
225. Valverde AM, Sinnett-Smith J, Van Lint J, Rozengurt E., 1994. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc Natl Acad Sci USA. 91:8572–8576.
226. Varga A, Czifra G, Tallai B, Nemeth T, Kovacs I, Kovacs L, Biro T., 2004. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol. 46:462–465.
227. Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA., 2008. PKC gamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci. 121:2339–2349.
228. Violin JD, Zhang J, Tsien RY, Newton AC., 2003. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. J Cell Biol. 161:899–909.
229. Wang HQ, Smart RC., 1999. Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion. J Cell Sci. 112: 3497–3506.
230. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F., 2015. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell. 163:1237–1251.
231. Wang Y, Wang Y, Zhang H, Gao Y, Huang C, Zhou A, Zhou Y, Li Y., 2016. Sequential posttranslational modifications regulate PKC degradation. Mol Biol Cell. 27:410–420.
232. Watanabe M, Chen C-Y, Levin DE., 1994. Saccharomyces cerevisiae PKC1 encodes a protein kinase C (PKC) homolog with a substrate specificity similar to that of mammalian PKC. J Biol Chem. 269:16829–16836.
233. Weber J, Hecker E., 1978. Cocarcinogens of the diterpene ester type from Croton flavens L. and esophageal cancer in Curaçao. Experientia. 34:679–682.
234. Wender PA, Cribbs CM, Koehler KF, Sharkey NA, Herald CL, Kamano Y, Pettit GR, Blumberg PM., 1988. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci U S A. 85:7197–7201.
235. Wu-Zhang AX, Newton AC., 2013. Protein kinase C pharmacology: refining the toolbox. Biochem J. 452:195–209.
236. Wu-Zhang AX, Schramm CL, Nabavi S, Malinow R, Newton AC., 2012. Cellular pharmacology of Protein Kinase Mzeta (PKMzeta) contrasts with its in vitro profile: implications for PKMzeta as a mediator of memory. J Biol Chem. 287:12879–12885.
237. Yamanaka T, Horikoshi Y, Sugiyama Y, Ishiyama C, Suzuki A, Hirose T, Iwamatsu A, Shinohara A, Ohno S., 2003. Mammalian Lgl forms a protein complex with PAR-6 and aPKC independently of PAR-3 to regulate epithelial cell polarity. Curr Biol. 13:734–743.
238. Yang Y, Igumenova TI., 2013. The C-terminal V5 domain of protein kinase Cα is intrinsically disordered, with propensity to associate with a membrane mimetic. PLoS One. 8:e65699.
239. Yeong SS, Zhu Y, Smith D, Verma C, Lim WG, Tan BJ, Li QT, Cheung NS, Cai M, Zhu YZ, et al. 2006. The last 10 amino acid residues beyond the hydrophobic motif are critical for the catalytic competence and function of protein kinase Calpha. J Biol Chem. 281:30768–30781.
240. Zhang LL, Cao FF, Wang Y, Meng FL, Zhang Y, Zhong DS, Zhou QH., 2015. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin Transl Oncol. 17:371–377.
241. Zhou J, Adams JA., 1997. Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase. Biochemistry. 36:15733–15738.
242. Zurgil U, Ben-Ari A, Atias K, Isakov N, Apte R, Livneh E., 2014. PKCη promotes senescence induced by oxidative stress and chemotherapy. Cell Death Dis. 5:e1531.